These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 8667054)
21. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. Quirijnen JM; Han SH; Zonnenberg BA; de Klerk JM; van het Schip AD; van Dijk A; ten Kroode HF; Blijham GH; van Rijk PP J Nucl Med; 1996 Sep; 37(9):1511-5. PubMed ID: 8790203 [TBL] [Abstract][Full Text] [Related]
22. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Palmedo H; Bender H; Dierke-Dzierzon C; Carl UM; Risse J; Krebs D; Biersack HJ Clin Nucl Med; 1999 Sep; 24(9):643-8. PubMed ID: 10478737 [TBL] [Abstract][Full Text] [Related]
27. Rhenium-188-HEDP in the palliative treatment of bone metastases. Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533 [TBL] [Abstract][Full Text] [Related]
28. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer. Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554 [TBL] [Abstract][Full Text] [Related]
29. [Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate]. Lerch H Strahlenther Onkol; 1998 Jul; 174(7):384-5. PubMed ID: 9689963 [No Abstract] [Full Text] [Related]
30. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552 [TBL] [Abstract][Full Text] [Related]
31. 186Re-HEDP for metastatic bone pain in breast cancer patients. Lam MG; de Klerk JM; van Rijk PP Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846 [TBL] [Abstract][Full Text] [Related]
32. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074 [TBL] [Abstract][Full Text] [Related]
33. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors. Scher HI; Curley T; Yeh S; Tong W; O'Moore PV; Larson S Adv Exp Med Biol; 1992; 324():115-29. PubMed ID: 1283494 [No Abstract] [Full Text] [Related]
34. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group. Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M; Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368 [TBL] [Abstract][Full Text] [Related]
35. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405 [TBL] [Abstract][Full Text] [Related]
36. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Palmedo H; Guhlke S; Bender H; Sartor J; Schoeneich G; Risse J; Grünwald F; Knapp FF; Biersack HJ Eur J Nucl Med; 2000 Feb; 27(2):123-30. PubMed ID: 10755716 [TBL] [Abstract][Full Text] [Related]
37. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Graham MC; Scher HI; Liu GB; Yeh SD; Curley T; Daghighian F; Goldsmith SJ; Larson SM Clin Cancer Res; 1999 Jun; 5(6):1307-18. PubMed ID: 10389913 [TBL] [Abstract][Full Text] [Related]
38. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP. Samaratunga RC; Thomas SR; Hinnefeld JD; Von Kuster LC; Hyams DM; Moulton JS; Sperling MI; Maxon HR J Nucl Med; 1995 Feb; 36(2):336-50. PubMed ID: 7830140 [TBL] [Abstract][Full Text] [Related]
39. Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Maxon HR; Deutsch EA; Thomas SR; Libson K; Lukes SJ; Williams CC; Ali S Radiology; 1988 Feb; 166(2):501-7. PubMed ID: 3122267 [TBL] [Abstract][Full Text] [Related]
40. Advances in our understanding of the treatment of painful bone metastasis. Siberstein EB J Nucl Med; 2000 Apr; 41(4):655-7. PubMed ID: 10809605 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]